Drugs used for postmenopausal hormone replacement therapy
| Oestrogen | Type | Average daily dose |
| Oral | Micronised oestradiol | 2 mg |
| Conjugated oestrogens | 0.625 mg | |
| Oestradiol valerate | 2 mg | |
| Piperazine oestrone sulphate | 0.625 mg | |
| Transdermal | Oestradiol in adhesive matrix or reservoir patch | 50 μg |
| Oestradiol in a gel formulation | 2.5 g | |
| Subcutaneous pellets | Administered at six monthly intervals | 50 mg |
| Vaginal applications | These are administered daily for three weeks followed by twice weekly administration to minimise unopposed oestrogen effect on the uterus | |
| Oestriol cream | ||
| Oestradiol vaginal tablets | ||
| Conjugated equine oestrogen cream | ||
| Progestational agents | Average daily dose (sequential regimen) | |
| Micronised progesterone | 300 mg | |
| 19-Nortestosterone derivatives | ||
| Norethisterone | 1 mg | |
| Levonorgestrel | 0.075 mg | |
| Norgestrel | 0.150 mg | |
| 17 Acetoxy derivatives of progesterone: medroxyprogesterone acetate | 10 mg | |
| C-21 Progestin: dydrogesterone | 10–20 mg | |
| Other synthetic compounds | ||
| Tibolone | 2.5 mg | |
| Raloxifene | 60 mg | |